Aldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. Aldeyra’s lead product candidate, reproxalap (formerly NS2), is an aldehyde trap in development for allergic conjunctivitis, anterior uveitis, and other forms of ocular inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism.
Sjögren-Larsson Syndrome is a rare genetic inborn error of aldehyde metabolism, characterized by severe skin disease (ichthyosis) and neurological disorders. There is no FDA-approved therapy for Sjögren-Larsson Syndrome.
Noninfectious Anterior Uveitis
Noninfectious Anterior Uveitis is a rare but severe and potentially blinding inflammatory disease characterized in part by high aldehyde levels that may cause increased numbers of inflammatory cells in the front of the eye, leading to pain, redness, loss of vision, and other ocular symptoms.
Allergic Conjunctivitis is a common allergic disease that affects more than 20% of the population worldwide. The disease is thought to be mediated in part by pro-inflammatory aldehydes, and is characterized by inflammation of the conjunctiva (a membrane covering the front part of the eye), resulting in ocular itching and excessive tear production.
Succinic Semi-aldehyde Dehydrogenase Deficiency
Aldeyra is also developing a potential therapy for Succinic Semi-aldehyde Dehydrogenase Deficiency, a neurological disease caused by genetic mutations that result in elevated levels of succinic semi-aldehyde, a toxic aldehyde that is converted to other metabolites that can cause severe neurological dysfunction.